1. Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial
   Francesco Tovoli et al, 2017, Future Oncology CrossRef
2. null
   Bakiye Goker Bagca et al, 2017 CrossRef
3. Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
   Francesco Tovoli et al, 2018, Hepatic Oncology CrossRef
4. The role of tumor microenvironment in resistance to anti-angiogenic therapy
   Shaolin Ma et al, 2018, F1000Res CrossRef
5. Comparison of the human tumor metastasis gene expression level in neuroblastoma patients with MYCN amplification and 2p gain: Pilot study
   Katarzyna Szewczyk, 2018, Pediatric Hematology Oncology Journal CrossRef
6. Endothelial Colony-Forming Cell Function Is Reduced During HIV Infection
   Samir K Gupta et al, 2018 CrossRef
7. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate
   Jiaqi Mi et al, 2018, J. Biol. Chem. CrossRef
8. Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
   Pei-Wen Yang et al, 2019, Front. Oncol. CrossRef
9. Developing preclinical models of neuroblastoma: driving therapeutic testing
   Kimberly J. Ornell et al, 2019, BMC biomed eng CrossRef
10. Cabozantinib for relapsed neuroblastoma: Single institution case series
    Michael P. Perisa et al, 2020, Pediatr Blood Cancer CrossRef
11. Overexpression of miR-101 promotes TRAIL-induced mitochondrial apoptosis in papillary thyroid carcinoma by targeting c-met and MCL-1
    Jie Zhu et al, 2017, Oncotarget CrossRef
12. The untold stories of the speech gene, the FOXP2 cancer gene
    Maria Jesus Herrero et al, 2018, Genes Cancer CrossRef
13. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
    Runze Shang et al, 2020, Gut CrossRef
14. MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment
    Konstantinos Zormpas-Petridis et al, 2019, Cancer Res CrossRef
15. Phase 1b/2 trial of tepotinib in sorafenibpretreated advanced hepatocellular carcinoma with MET overexpression
    Thomas Decaens et al, 2021, Br J Cancer CrossRef
16. Mesenchymal Epithelial Transition Factor Signaling in Pediatric Nervous System Tumors: Implications for Malignancy and Cancer Stem Cell Enrichment
    Amanda Rose Khater et al, 2021, Front. Cell Dev. Biol. CrossRef
17. When the MET receptor kicks in to resist targeted therapies
    Marie Fernandes et al, 2021, Oncogene CrossRef
18. Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence
    Matteo Santoni et al, 2021, Expert Review of Anticancer Therapy CrossRef
19. Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes
    Timofey Lebedev et al, 2021, Oncogene CrossRef
20. Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology
    Esteban Javier Rozen et al, 2021, Cancer Metastasis Rev CrossRef
21. Antitumor effect of polyphyllin D on liver metastases of neuroblastoma
    Yasuhiro Kondo et al, 2022, Pediatr Surg Int CrossRef
22. The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents
    Megan Grundy et al, 2022, Front. Pediatr. CrossRef
23. Design and biological evaluation of 3-substituted quinazoline-2,4(1H,3H)-dione derivatives as dual c-Met/VEGFR-2-TK inhibitors
    Abdelfattah Hassan et al, 2023, Journal of Enzyme Inhibition and Medicinal Chemistry CrossRef
24. Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy
    Erica A. Steen et al, 2023, Biochemical Pharmacology CrossRef